In particular, further evaluation of possible non-insulinemic pathways influenced by GIPR signaling could help to reconcile the specificity of the E354 association with breast cancer risk given the important role of metabolic dysfunction across the 5 other cancers examined in this analysis. The gene discussed is GIPR; the disease is breast cancer.